结构比较和治疗效果对性结肠炎的福科伊丹及其衍生品从Saccharina japonica
Yanlei Yu1, Xiaoshu Jin1, Yunjie Zhao1
1College of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China.
Marine drugs
|November 26, 2025
概括
富科伊丹 (CF) 和其降解衍生物 (DF) 在治疗性结肠炎 (UC) 中表现有前途. 虽然两者都能缓解症状,但DF更有效地恢复了肠道微生物群的多样性,并保护了结肠.
科学领域:
- 海洋生物技术 海洋生物技术
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病 (IBD),与包括结肠直肠癌在内的重大健康风险有关.
- 富科伊丹 (Fucoidan) 是棕藻中的硫酸多糖,对UC具有潜在的治疗作用,但其结构-活性关系需要阐明.
- 了解福科丹的结构变异如何影响其疗效对于开发向性UC治疗至关重要.
研究的目的:
- 为了比较本地福科伊丹 (CF) 和其降解衍生物 (DF) 在预防和治疗UC的治疗效果.
- 在UC小鼠模型中研究CF和DF之间的独特作用机制和结构差异.
- 评估CF和DF对肠道微生物群组成和UC多样性的影响.
主要方法:
- CF (582 kDa) 和DF (2.3 kDa) 的结构特征,包括单糖化合物组成,硫化含量和分子量.
- 在接受CF或DF治疗的小鼠模型中评估UC临床症状,疾病活性指数 (DAI),体重减轻和结肠长度.
- 结肠组织的组织病理学分析,以评估粘膜保护和炎症透.
- 使用16S rRNA测序来确定微生物多样性和组成的肠道微生物群分析.
主要成果:
- 无论是CF还是DF都显著缓解了UC的临床症状,并改善了DAI,但机制不同.
- 肺结核在预防体重减轻和保持结肠长度方面更有效,而肺结核在保护结肠粘膜并减少炎症方面更有效.
- 与CF相比,DF在UC小鼠中表现出更大的恢复微生物多样性和调节特定微生物失衡的能力.
结论:
- 富科伊丹 (CF) 和其降解衍生物 (DF) 在管理UC方面是有效的,具有明显的治疗特征.
- 由于DF的分子量较小,分支较少,这可能有助于其增强的肠道微生物群恢复和粘膜保护作用.
- 这些发现凸显了富可伊丹在抗UC活性中的结构特征的重要性,并表明了开发定制的基于富可伊丹的疗法的潜力.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
435
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
435
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
Inflammatory Bowel Disease I: Ulcerative Colitis
876
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
876
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469
Inflammatory Bowel Disease IV: Pharmacological Management
452
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
452
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
553
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
553


